[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@hhashmi87 Avatar @hhashmi87 Hamza Hashmi

Hamza Hashmi posts on X about events, 12m, rx, tec the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: X #

Mentions Line Chart

Followers: XXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social topic influence events 16.67%, 12m 16.67%, rx 16.67%, tec 16.67%, stem 8.33%, future 8.33%, we will 8.33%, emd 8.33%, fu 8.33%, rates #427

Top accounts mentioned or mentioned by @surbhisidanamd @tombmt133 @hadidisamer @rahulbanerjeemd @ashhematology @slentzsch @marivimateos @bloodportfolio @aschavgoulidze @perrotaurore @myelomadoc @rajshekharucms @jnjinnovation @larvol @gkaurmd @algarfall @phari

Top assets mentioned Frontline Ltd. (FRO)

Top Social Posts

Top posts by engagements in the last XX hours

"3) Efficacy: Tec-Dara vs DPD/DVD ➡3 yr PFS XX% vs XX% (HR=.17) ➡3yr OS XX% vs XX% (HR=0.46) ➡Better CR (80% vs 30%) & MRD neg 10-5 XX% vs XX% 💡Some early PFS events w Tec Dara w all those who sustained responses 12m relapse free and alive at 36m #FlattenTheCurve 💡15% RRMM remain ultra-high risk and declare themselves 6m #UnMetNeed"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements

"This is one of the largest RWE for stem cell boost for post CAR T cytopenias being presented at #ASH25 pts w severe refractory cytopenias recovered counts quickly and effectively with previously stored stem cells"
X Link 2025-12-04T19:49Z XXX followers, XXX engagements

"5) Take home Message: 💡Tec Dara as effective as CAR T as 2L Rx (3yr PFS for SR in CART-4 80%) 💡No risk of NINT and enterocolitis 💡Risk of BCMA loss/ mutations & T-cell exhaustion 💡Need for ongoing Rx risk of infections need for IVIG 💰💰💰 💡Needs to be time limited Rx guided by MRD neg (12m) to address these issues #LimiTEC 💡Ideal pt: relapse on Len maintenance not ideal for Ciltacel (old frail cognitive or caregiver or access issues)✅ for CD38 for those progressing on monthly Dara 💡Prefer CART in those high risk (15%) progressing 6m on Tec-Dara in trial 💡While BsAb are easy for"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements

"6) Future directions: 💡Time to MRD negativity w Tec Dara and cessation of Rx (12m) 💡RWE for Dara exposed & Ref pts receiving Tec and Dara as 2L 💡BCMA loss/mutations in the early progressors on Tec Dara; Is CAR T still going to work 💡Educate community providers to continue to refer pts at first relapse to discuss all options 💡Unclear how long we will debate CAR T vs Tec Dara as 2L as Tec (MAJ-7) and CAR T (MAJ-5 CAR T-6) will likely make it to first line"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements

"Oral Abstract: @Marivimateos: 3yr F/u of Tec+Talq for RRMM ORR XX% CR XX% X yr PFS XX% G3 infection XX% hypogamma XX% infection risk w time but remains significant. More pts w EMD penta refractory prior BCMA Rx than CAR T-1. CART is still one & done. #ASH25 #MMSM"
X Link 2025-12-07T22:45Z XXX followers, XXX engagements

"4) Adverse events: ➡CRS XX% (no prophy Toci allowed) mostly G1 ICANS X% ➡G3 infection XX% vs XX% (IVIG encouraged but only mandated after 2/2023) ➡MM related symptoms over time due to disease control 💡Infection rates decreased w Q4 dosing mandated IVIG use and better myeloma control #IVIGforAll 💡Initial cross over of OS curves due to infection related deaths 💡Imp to look at PRO data and see if decline beyond 12m Rx due to ongoing Rx"
X Link 2025-12-09T14:00Z XXX followers, XXX engagements

"Presented at #IMS25 now in @BloodPortfolio 👉22% of NDMM HR by new IMWG Consensus Genomic model 👉CD38 Ab & ASCT had PFS for both SR and HR 👉If no HR genomics B2M had similar outcomes as normal B2M #MMSM #MedTwitter @ASchavgoulidze 👏👏"
X Link 2025-09-30T13:34Z XXX followers, 4253 engagements

"Oral Abstract 0697: @Myeloma_Doc showing LINKER-MM4 data on linvo in NDMM: despite high disease burden grade X CRS XX% G3 infection XX% in first 3m early & deep responses MRD neg (100%). Rates of infection remain as frontline Rx all pts on BsAb should get IVIG #ASH25 #MMSM"
X Link 2025-12-07T21:42Z XXX followers, XXX engagements

"Oral abstract 0699: Adam Cohen on Cevo x6m as post BCMA CAR T consolidation to achieve MRD negativityn=27 mostly cilta-cel all pts MRD neg before Cevo. Unusual immune AE seen. Should look into ide-cel pts & those who are MRD+ at D30 and with high risk dx EMD #ASH25 #MMSM"
X Link 2025-12-07T22:15Z XXX followers, XXX engagements

"@rajshekharucms IMO time limited Rx should be guided by time to MRD negativity data in the trial. XX% achieved MRD neg by 10-6 (evaluable dataset) vast majority sustained at 6m. I would suggest stopping Rx at 12m if MRD neg. No drop in the PFS curve beyond 12m #MMSM #ASH25"
X Link 2025-12-09T16:47Z XXX followers, 3233 engagements